Department of Epileptology, University Hospital Bonn, Venusberg-Campus 1, 53127 Bonn, Germany.
Department of Epileptology, University Hospital Bonn, Venusberg-Campus 1, 53127 Bonn, Germany.
Seizure. 2020 Aug;80:92-95. doi: 10.1016/j.seizure.2020.06.012. Epub 2020 Jun 8.
A special component of cannabis, cannabidiol (CBD), is currently in the focus of epilepsy treatment and research. In this context, we investigated patients' expectations and preferences pertaining to plant-derived versus synthetic formulation of cannabidiol, as well as their willingness to get this treatment.
One hundred and four of 153 patients with different forms of epilepsy (54 % female, mean age 40 ± 16 yrs.) responded to the survey. The survey consisted of 8 questions addressing expectations of and concerns towards CBD treatment, preferences of plant-derived versus synthetic CBD, estimated monthly costs, and willingness to buy CBD at one's own expense.
The majority (73 %) of the responding epilepsy patients wished to receive plant-derived CBD; 5 % preferred synthetic CBD. Reasons for this choice were botanic origin, lack of chemistry, and the assumption of fewer and less dangerous side effects. Eighty-two percent of the patients estimated the monthly costs of CBD treatment to be below €500. Using the willingness-to-pay approach to assess the commitment of patients, 68 % could imagine buying the drug themselves. Fifty-three percent of these would be willing to pay up to €100, 40 % €100 to €200, and another 7 % €200 to €500 per month.
There is an overwhelming preference towards plant-derived cannabidiol in epilepsy patients, driven by the idea of organic substances being safer and better tolerated than synthetic. The willingness-to-pay approach reflects the high burden and pressure of uncontrolled epilepsy and the expectation of relief. Non-realistic ideas of pricing as well as what patients would be willing and able to pay confirm this perception.
大麻的一种特殊成分，即大麻二酚（CBD），目前是治疗癫痫的焦点。在这方面，我们调查了患者对植物源性与合成 CBD 制剂的期望和偏好，以及他们接受这种治疗的意愿。
153 名癫痫患者中有 104 名（54%为女性，平均年龄 40±16 岁）对调查做出了回应。该调查包括 8 个问题，涉及对 CBD 治疗的期望和担忧、对植物源性与合成 CBD 的偏好、估计的每月费用，以及自费购买 CBD 的意愿。
大多数（73%）接受调查的癫痫患者希望接受植物源性 CBD；5%的患者更喜欢合成 CBD。做出这种选择的原因是植物来源、缺乏化学物质以及假设副作用更少且更危险。82%的患者估计 CBD 治疗的每月费用低于 500 欧元。通过意愿支付的方法来评估患者的承诺，68%的患者可以想象自己购买这种药物。其中 53%的人愿意支付高达 100 欧元，40%的人愿意支付 100 至 200 欧元，另有 7%的人愿意支付 200 至 500 欧元。
癫痫患者对植物源性大麻二酚有压倒性的偏好，这是因为有机物质比合成物质更安全、更耐受的想法。意愿支付的方法反映了不受控制的癫痫的高负担和压力，以及对缓解的期望。不切实际的定价观念以及患者愿意和能够支付的金额证实了这一观点。
